Talazoparib 0.35 mg [Talzenna]
RxNorm 2639965

Concept Hierarchy & Relationship Mapping

RxNorm Concept Unique Identifier (RxCUI) 2639965 represents a standardized clinical drug concept used for cross-system interoperability. This concept aggregates multiple Atom IDs (AUIs), which are specific naming variations and synonyms used across pharmaceutical databases to ensure accurate medication mapping for: talazoparib 0.35 mg [Talzenna].

The following semantic concepts and normalized strings are associated with this clinical entity:

SBDC
Talazoparib 0.35 mg [Talzenna]
AUI:12816884
View

This clinical crossover tool is designed for healthcare professionals, pharmacists, and data analysts to safely compare substitute products and manage medication interoperability.

SBDCPrescribable

Semantic Branded Drug Component (SBDC):
Talazoparib 0.35 mg [Talzenna]
(Atom ID: 12816884)

Clinical Status & Identity

Prescribable Status
YES (Active)
Part of the RxNorm Current Prescribable Content subset including all drugs available for prescription in the USA.
Concept Description
talazoparib 0.35 MG [Talzenna]
Official description of the drug concept as defined in the source vocabulary.
Suppress Flag
N
N: Not suppressible | O: Obsolete | Y: Suppressed by editor | E: Unquantified non-prescribable drug.

Interoperability & Coding

Concept ID (RxCUI)
2639965
RxNorm Unique Identifier for the standardized concept.
Atom ID (RXAUI)
12816884
Unique identifier for this specific name variation (Atom).
Term Type (TTY)
SBDC
Semantic Branded Drug Component (Ingredient + Strength + Brand Name)
Source Code
2639965
The "Most useful" identifier asserted by the original source vocabulary.

Source & Registry Data

Source Name
RxNorm Vocabulary (RXNORM)
The official name and abbreviation for the vocabulary source.
Source Version
20AA_260601F
The specific version of the vocabulary provided by the source.
Update Date
June 01, 2026
The date when this RxNorm data was last updated by the NLM.
License Contact
RxNorm Customer Service, , U.S. National Library of Medicine, 8600 Rockville Pike, , Bethesda, MD, United States, 20894, (888) FIND-NLM, , https://support.nlm.nih.gov/support/create-case/, https://www.nlm.nih.gov/research/umls/rxnorm/
Source licensing contact information.

Patient Education

Talazoparib


Talazoparib is used alone to treat certain types of breast cancer that has spread within the breast or to other areas of the body. Talazoparib is also used with enzalutamide (Xtandi) to treat certain types of prostate cancer that has spread to other parts of the body in men and who have not been helped by certain medical and surgical treatments that decrease testosterone levels. Talazoparib is in a class of medications called poly (ADP-ribose) polymerase (PARP) inhibitors. It works by stopping or slowing the growth of cancer cells.
[Learn More]


* Please review the disclaimer below.